SCOPE X 2026: Clinical Ops, Data, and AI in Boston

Key Takeaways

• SCOPE X 2026 is a clinical research event organized by IQVIA in Boston.
• The event concentrates on clinical operations, data services, data scientists, technology, and AI.
• While the event is scheduled for May 2026, specific dates are not yet available.

IQVIA's SCOPE X 2026, a two-day event focusing on clinical operations, data services, and AI in clinical research, will be held in Boston in May 2026. The event aims to address key industry challenges and advancements in clinical trial processes.

Event Overview

SCOPE X 2026, organized by IQVIA, is designed to bring together experts and professionals in clinical operations, data science, and technology. The conference will explore strategies for optimizing clinical trials, leveraging data for better research outcomes, and implementing AI solutions.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for general. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Focus Areas

• Clinical Operations: Discussions will cover strategies for streamlining and optimizing clinical trial processes to improve efficiency and reduce costs.
• Data Services: The event will highlight how data can be leveraged to improve clinical research outcomes, focusing on data management, analysis, and interpretation.
• AI and Technology: SCOPE X 2026 will explore the implementation of artificial intelligence and other advanced technologies in clinical trials to accelerate drug discovery and development.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Potential Discussion Topics

• Addressing the challenges in clinical trial design and execution.
• The crucial role of data scientists in advancing clinical research.
• Exploring the latest advancements in AI for drug discovery and development.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for general pricing, access, and launch sequencing.

Market & Investor Implications

While specific pharmaceutical trial data readouts are not yet linked to SCOPE X 2026, the event's focus on optimizing clinical trials through data and AI could signal future investment and strategic partnerships in these areas. The conference may highlight emerging technologies and methodologies that could impact the efficiency and success rates of clinical development programs.

IntelligenceStrategic Takeaways▾

SCOPE X 2026 is a clinical research event organized by IQVIA in Boston. The event concentrates on clinical operations, data services, data scientists, technology, and AI. While the event is scheduled for May 2026, specific dates are not yet available.

What to Watch Next

As the event date approaches, keep an eye out for announcements regarding specific speakers, presentation topics, and any late-breaking abstracts that may be presented. Further details on the event schedule and confirmed participants will provide a clearer picture of the key insights and takeaways from SCOPE X 2026.

Frequently Asked Questions

• What is SCOPE X 2026?

  SCOPE X 2026 is a clinical research event organized by IQVIA in Boston, focusing on clinical operations, data services, and AI.

• When and where will SCOPE X 2026 take place?

  The event is scheduled for May 2026 in Boston, though specific dates have yet to be announced.

• What are the main topics covered at SCOPE X 2026?

  The event will focus on clinical operations, data services, and the application of AI and technology in clinical trials.

• Who is the event organizer for SCOPE X 2026?

  IQVIA is the organizer of SCOPE X 2026.

References

1. IQVIA SCOPE X 2026 Event Page
2. Lunit to Present Five Studies at ASCO 2026
3. RenovoRx Announces Data from TIGeR-PaC Trial at ASCO 2026

Related coverage

• Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation Story
• Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts
• Breast Cancer Statistics Worldwide: What the Data Shows